Back to Search
Start Over
Predictive and Prognostic 18 F-Fluorocholine PET/CT Radiomics Nomogram in Patients with Castration-Resistant Prostate Cancer with Bone Metastases Treated with 223 Ra.
- Source :
-
Cancers [Cancers (Basel)] 2024 Jul 29; Vol. 16 (15). Date of Electronic Publication: 2024 Jul 29. - Publication Year :
- 2024
-
Abstract
- Purpose: We aimed to develop a nomogram able to predict treatment failure, skeletal events, and overall survival (OS) in patients with castration-resistant prostate cancer with bone metastases (CRPC-BM) treated with Radium-223 dichloride ( <superscript>223</superscript> Ra).<br />Patients and Methods: Patients from the Castilla-La Mancha Spanish region were prospectively included in the ChoPET-Rad multicenter study from January 2015 to December 2022. Patients underwent baseline, interim, and end-of-treatment bone scintigraphy (BS) and <superscript>18</superscript> F-Fluorocholine PET/CT (FCH PET/CT) scans, obtaining multiple imaging radiomics as well as clinical and biochemical variables during follow-up and studying their association with the previously defined end-points. Survival analysis was performed using the Kaplan-Meier method and Cox regression. Multivariate logistic and Cox regression models were calculated, and these models were depicted by means of nomograms.<br />Results: Median progression-free survival (PFS) and OS were 4 and 14 months (mo), respectively. The variables that showed independent and significant association with therapeutic failure were baseline alkaline phosphatase (AP) levels ( p = 0.022) and the characteristics of BM on the CT portion of PET/CT ( p = 0.017). In the case of OS, the significant variables were therapeutic failure ( p = 0.038), the number of lines received after <superscript>223</superscript> Ra ( p < 0.001), average SUVmax ( p = 0.002), bone marrow infiltration in FCH PET/CT ( p = 0.006), and interim FCH PET/CT response ( p = 0.048). Final nomograms included these variables, showing good discrimination among the 100 patients included in our study. In the study of skeletal events, only OS showed a significant association in the multivariate analysis, resulting in an inconsistent nomogram design.<br />Conclusions: FCH PET/CT appears to be a good tool for evaluating patients eligible for treatment with <superscript>223</superscript> Ra, as well as for their follow-up. Thus, findings derived from it, such as the morphological characteristics of BM in the CT, bone marrow infiltration, or the response to <superscript>223</superscript> Ra in the interim study, have proven to be solid and useful variables in the creation of nomograms for predicting therapeutic failure and OS.
Details
- Language :
- English
- ISSN :
- 2072-6694
- Volume :
- 16
- Issue :
- 15
- Database :
- MEDLINE
- Journal :
- Cancers
- Publication Type :
- Academic Journal
- Accession number :
- 39123422
- Full Text :
- https://doi.org/10.3390/cancers16152695